Neurocrine Biosciences Inc.’s (NBIX) Ingrezza oral granules, a new sprinkle formulation of Ingrezza capsules for oral administration, awaits the FDA decision on April 30, 2024.Ingrezza is currently available as the only one-capsule, once-daily treatment option with no complex titration for adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease.The proposed new formulation of Ingrezza, i.e., as oral granules capsules, offers an alternative administration option for those patients who have difficulty swallowing or simply prefer not to take whole capsules.The net product sales of Ingrezza were $1.84 billion in full year 2023, representing year-over-year growth of 29%. For full year 2024, the company expects the drug to bring home net product sales of $2.1 billion to $2.2 billion.NBIX is currently (Mar.28, 2024) trading at $137.94, up 0.09%.